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Rejection was more common for manufacturer’s comments on outcomes (6/8; 75%) 
and comparators (8/13; 61.5%). Rate of final recommendation by NICE was higher 
for those MS where all (29/40; 74%) or certain changes (14/20; 74%) requested by 
the manufacturer were implemented in the final scope than for those where NICE 
rejected all manufacturer requests (7/11; 64%), and similar to overall recommenda-
tion rate (66/91; 73%). ConClusions: These data highlight that the initial scope 
frequently does not meet manufacturer’s expectations. However, manufacturer’s 
suggestions are often incorporated in the final scope. NICE not implementing manu-
facturer’s suggestions to the final scope does not decrease the likelihood of being 
granted funding.
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objeCtives: Biosimilars and biobetters are subsequent versions of licensed innova-
tor biotherapeutics. Whereas biosimilars are comparable to the originator product 
in terms of quality, safety and efficacy, biobetters incorporate intentional modifi-
cations to the originator molecular profile with the aim of producing a superior 
product. This distinction between biosimilars and biobetters has important impli-
cations from a regulatory perspective, with biosimilars following class-specific 
guidance whereas biobetters are considered innovator drugs. This study sought 
to examine and compare the regulatory and reimbursement approaches to the 
appraisal of biobetters and biosimilars. Methods: Biobetters and biosimilars of 
the same product class were identified, and qualitative analyses of the recommen-
dations by indication, evidence considered, and key decision drivers were under-
taken using available regulatory and HTA reimbursement decision documentation 
from six European countries. Results: Findings for filgrastim are presented as 
an example; 7 biosimilars, and the pegylated filgrastims (pegfilgrastim and lipegfil-
grastim) considered biobetters, were identified. Biosimilar filgrastims were granted 
European marketing authorisation based on demonstration of clinical comparabil-
ity to the originator filgrastim in one indication and extrapolation of the results 
to all 5 approved indications. Pegfilgrastim demonstrated clinical non-inferiority 
to filgrastim in one indication and was approved solely for this indication; the 
subsequently developed lipegfilgrastim was approved for the same indication but 
used pegfilgrastim as the comparator. Similar to biosimilar filgrastims, economic 
evidence in the form of cost-minimisation analyses was considered in HTA recom-
mendations of both pegylated filgrastims. This differs from the approach for certain 
other biobetters that have demonstrated clinical superiority and cost-effectiveness 
versus their originator. ConClusions: Biosimilars and biobetters are subject to 
distinct regulatory processes and the decision driving factors for reimbursement 
also differ among currently licensed biobetters. With the development of these 
products gaining momentum, it will be interesting to observe how the appraisal 
processes evolve to address the scope and variety of emerging biobetters.
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objeCtives: In Germany, with the introduction of the Pharmaceutical Market 
Restructuring Act (AMNOG) in January 1st2011, pricing and reimbursement deci-
sions for new drugs have been driven by the early benefit assessment (EBA). G-BA 
can decide to set or not a time limitation to the decision. The objectives of this 
study were, first, to review the number of time-limited decisions over time and 
second, to identify drivers of these decisions. Methods: G-BA’s decisions, from the 
introduction of AMNOG Law to June 1st2014, were reviewed. Exempted and/or 
cancelled procedures were excluded. Results: As of June 1st 2014, 76 EBAs were 
concluded and time limits, from 1 to 5 years, were imposed on 28% (21/76) of these 
decisions. Short-term restrictions (≤ 2 years) accounted for 52% (11/21) of the time-
limited decisions and long-term (> 2 years) for 48% (10/21). Time-limited decisions 
concerned largely oncology drugs (62%; 13/21), followed by endocrine/metabolic 
drugs (19%; 4/21) and neurology drugs (10%; 2/21). The number of time limited deci-
sions increased over the studied period, from none (0/2) of the decisions in 2011 to 
16% (3/19) in H1 2012, 38% (3/8) in H2 2012, 20% (3/15) in H1 2013, 35% (7/20) in H2 
2013 and reaching 42% (5/12) from January 1st to June 1st 2014 decisions. Time-limited 
decisions were triggered by one or several factors, with safety concerns being the 
major driver (38%; 8/21). Other drivers were uncertainties of outcomes (33%; 7/21), 
ongoing studies (33%; 7/21), lack of data (24% (5/21), European Medicine Agency’s 
(EMA) conditional approval (19%; 4/21), design uncertainty (10%; 2/21), inappropriate 
comparator (10%; 2/21), quality of life concerns (10%; 2/21), and EMA requirements 
for post-authorisation studies or risk management plan (10%; 2/21). ConClusions: 
An increasing trend for time-limited decisions was observed. Time restricted deci-
sions have become a major uncertainty management tool in Germany.
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objeCtives: Ultra-orphan diseases are extremely rare conditions many of which 
are severe, chronic, and progressive with high mortality rates. There is a growing 
number of therapies for ultra-rare diseases currently on the market. Reimbursement 
decisions for these therapies have been characterized by reduced evidence require-
ments with unmet need weighing heavily into health technology assessment (HTA) 
and reimbursement decision-making; as well as a generally wide pricing latitude. 
To gain insight into evolving market access requirements, we conducted a review 
of pan-European ultra-orphan therapy HTA requirements and reimbursement deci-
sions. Methods: Applying the National Institute for Health and Care Excellence 
(NICE) definition for ultra-orphan diseases (prevalence of ≤ 1/50,000), full European 
HTA reports on ultra-orphan therapies published through May 2014 were identified 
and reviewed to compare evidence requirements and reimbursement decisions 
across countries for health economic, clinical, and value based criteria. Results: 
Over sixty published ultra-orphan HTAs were identified across nine markets. A 
small portion of these submissions were rejected for reimbursement largely due 
to lack of evidence on clinical benefit. For therapies recommended with access 
restrictions, payers often requested additional follow-on studies or ongoing moni-
toring of patients by manufacturers. With respect to economic evidence evaluation, 
reimbursement decisions predominately hinged on therapy cost per patient per 
year, rather than cost-effectiveness. More recent assessments also evaluated qual-
ity of life evidence and input from patient groups. ConClusions: As health care 
budgets become more strained, ultra-orphan therapies priced at a premium have 
come under increased scrutiny from HTA agencies and payers to demonstrate value 
for money. In order to achieve optimal market access, manufacturers must consider 
continually evolving stakeholder evidence requirements and develop clinical and 
health economic value plans that demonstrate how their ultra-orphan therapies 
provide health gain instead of disease stabilization.
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objeCtives: Ultra-orphan diseases affect a very small patient population, defined 
by the National Institute for Health and Care Excellence (NICE) as those diseases 
with a prevalence of ≤ 1: 50,000. Medicines for these indications are difficult to 
develop in part due to challenges associated with recruiting for clinical trials 
from a small patient population. Within this context, global payer bodies have 
assessed these therapies with modified evidence requirements and opportunity 
for very high prices. We performed a health technology assessment (HTA) review 
of two ultra-orphan products – eculizumab/Soliris and iduronate-2-sulfatase (IDS)/
Elaprase – to gain insight into the evolving HTA evidence requirements for ultra-
orphan medicines and comparatively evaluate key decision drivers across geogra-
phies. Methods: We scanned global HTAs published before end of May 2014 to 
identify the two most widely assessed ultra-orphan therapies that have variable 
reimbursement decision outcomes (eculizumab/Soliris and IDS/Elaprase). To evalu-
ate pivotal decision drivers, we analyzed HTAs across several criteria, including 
clinical efficacy, unmet need, strength of evidence, cost-effectiveness and burden 
of illness. Results: We identified HTAs in seven countries. For both products, 
reimbursement decisions varied across agencies. Key decision drivers included 
cost-effectiveness, clinical efficacy, risk-sharing schemes, and lowered evidence 
requirements/ special criteria for ultra-orphan medicines. Assessments rejecting 
Soliris and Elaprase (e.g., Australia, Canada, UK) did so based on cost-effectiveness 
and lack of long-term survival data. Notably, the NICE Highly Specialized Technology 
Committee requested unprecedented justification of Soliris pricing. Some agencies 
(e.g, Scottish Medicines Consortium [SMC]) preemptively rejected the products due 
to manufacturer non-submission of required data. In Australia, Soliris gained recom-
mendation alongside a risk-sharing scheme while Elaprase gained recommendation 
under Life Saving Drugs Program criteria. ConClusions: Eculizumab and IDS are 
among a select list of therapies commanding very high prices globally. This study 
demonstrates variability in decision criteria and approaches across HTA agencies 
for such high-priced ultra-orphan products.
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objeCtives: Market access for an innovative technology, such as a biologic 
obtaining a license in a second indication, can be complex and time consuming. 
Reimbursement is critical to rapid adoption of and optimal patient access to a new 
technology. This study aimed to determine the best approach for communicating 
value and providing field-based staff with value resources to facilitate dialogue 
with stakeholders in various scenarios. Methods: We conducted desktop research 
of published literature, health technology assessment reports, clinical trials data, 
and third-party websites to identify the critical path and data most valuable to 
reimbursement decision making in order to prepare a communication resource. 
We conducted a country-affiliate workshop and qualitative one-on-one interviews 
with payer decision makers in several key markets to understand funding flow and 
the most appropriate means of communicating value to external decision mak-
ers. Results: The process and restrictions for biologics may be stricter than for 
other medications because of perceived high cost. There are multiple appropriate 
access pathways for various settings of care, all with varying requirements and 
value drivers. It is critical to understand the needs of external decision makers 
and provide field-based staff with a consistent yet customizable means of com-
municating the value of new technologies. All evidence and insights were synthe-
sized into an evidence-based market access value resource for key stakeholder 
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engagement. ConClusions: The evidence-based market access value resource 
approach provides a clear, concise, and globally integrated value story that will 
assist in market access and form the basis of consistent communication regarding 
value at the national, regional, and local level across external stakeholders (e.g., 
payer decision makers, physicians, patient advocates). Access for a biologics will be 
complex; regardless of pathway, decisions regarding reimbursement and adoption 
of a new technology are diverse and dispersed across and within countries, with 
varying levels of required evidence.
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The US significantly outspends all other top 10 developed nations, with no increase 
in life expectancy. Increasing transparency in health care spending could help 
address this cost to outcomes gap. CMS’ recent release of Medicare Part B Utilization 
and Payment data, covering 880,000 providers and $77 billion in Medicare pay-
ments, is a significant step toward this goal. objeCtives: Understand differences 
in billed versus paid amounts for provider and procedure types reported in Medicare 
data. Methods: Descriptive and inferential statistics were run on provider spe-
cialties representing greater than 2% of claims to describe the differences between 
maximum allowed Medicare payment amount, amount billed by providers, and 
the amount reimbursed. Geographical variation was also explored. Results: 
Amount billed is at least double the amount paid and double the maximum allow-
able amount for all of the specialties explored; amount billed versus paid varies 
significantly by specialty, with some specialties billing as much as six times what 
they are paid. Largest discrepancies were in anesthesiology (on average billing $838, 
versus $139 allowed and $110 paid). Other specialties with significant disparity 
include cardiology, diagnostic radiology, emergency medicine, ophthalmology, and 
orthopedic surgery; within certain specialties, specific procedures showed ranges 
of billing and payment ratios; across all specialties, average amount paid was about 
90% of maximum allowable; and each state is represented in line with census data 
for the Medicare population; state differences in amount paid versus billed and 
allowed is not significant. ConClusions: In analyzing payer and provider data to 
increase transparency on health care spend, we recognize there is heterogeneity 
between what is paid versus billed across specialty. There is an opportunity to focus 
attention on narrowing this gap for high-value procedures through evidence and 
education of patients, payers, and providers to ensure patients receive appropriate 
treatment, and providers are appropriately reimbursed.
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objeCtives: To assess the value and service quality of the National Health 
Insurance Scheme (NHIS) benefits. Methods: A review method was employed 
to analysis medical claims for the 2011 to 2013 period. The medical claims were 
retrieved from the database of the Ashiedu Keteke District NHIS Office. The incurred 
claims ratio, promptness of claims settlement, and claims rejection ratio indicators 
of benefit value and service quality were analyzed. Results: A total of 421,574 
medical claims with a cost of GHS7.3 million (USD2.6 million) were analyzed. 
These claims came from thirteen accredited health care providers-three public 
health facilities, four private clinics and six community pharmacies. The incurred 
claims ratio increased significantly from 4.3 to 7.2 over the period, 2011-2013. The 
proportion of claims settled beyond 90 days increased consistently from 26% to 
90% over the same period. Although, the proportion of claims rejected increased 
from 0.9% to 3.6% over the period under review, overall, it was low. The reasons for 
rejection included provision of benefits to inactive subscribers and breach of sub-
limit on certain expense category. ConClusions: There is increased awareness 
and utilization of health services; however, there are considerable delays in claims 
settlements. It would be necessary for management of the NHIS to settle claims 
in time to ensure that health care providers are financially resourced to render 
service to subscribers.
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objeCtives: Our team wanted to compare the economic effect of restricted mar-
ket access and reference based pricing (RBP) vs. RBP alone in two consecutive 
periods, 2007—2009 and 2010—2012. Methods: We used the officially published 
cash flow statements and income statements from the financial reports of the 
National Health Insurance Fund (NHIF) for each of the years from 2007 to 2012. 
Then we compared the data about the expenditure for drugs, as well as the data 
about the budget control. Results: While restricted market access and RBP has 
been applied between 2007 and 2009, the NHIF drug expenditure increased with 
15% (from EUR 144 mln to EUR 166 mln). For that period, the drug expenditure 
was generally 100% within the budget. From 2010 to 2012, while only RBP has been 
applied, the expenditure increased with 62% (from EUR 187 to EUR 303 mln). For 
the period, the drug expenditure exceeded the NHIF budget with 5% in 2010, 34% in 
2011, 20% in 2012. ConClusions: RBP alone cannot control the drug expenditure 
in a long-term. Additional measures are needed together with RBP. Performance-
based pricing, differential pricing, comparative pricing, profit control and price-
volume agreements may be considered as additional to RBP measures for pricing 
and budget control.
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objeCtives: The part of Hungarian drug provision system, which is available 
on social welfare list, changed several times and in different extents in recent 
years. The introduction of drug budget in 2006 and simultaneously the abolition 
of social welfare drug list implied the most significant change. The chief aim of 
our analysis to give a comprehensive overview about the main trends on this field 
examining the range of available products on social welfare list based on different 
aspects, also concerning the trends of demand, product structure, expenditures 
and patient burdens. Methods: Changes of key points of relevant acts concerned 
in drug provision, the aggregated (not patient level) public turnover data of the 
Hungarian Health Fund and published number of patients involved in this reim-
bursement category were considered as the key sources and indicators of our 
evaluation. Results: After regulation changes, demand (DOT) and number of 
patients within social welfare list category significantly decreased after 2006 until 
2009, but since then both of them stagnate. Significant growth of reimbursement 
outflow within this segment can be observed until 2011, but after slight decrease. 
Part share of higher level reimbursement categories within reimbursement out-
flow increased. Demand moved to more expensive products, while patients were 
able to access to more innovative active ingredients in higher level reimburse-
ment categories. Strong correlation can be observed between changes of acts and 
breaks in turnover trends. ConClusions: Results of the analysis may support 
objective judgement of the present social welfare provision system, as well as 
may contain considerable consequences regarding to potential ways of future 
structural changes, considering both interests of entitled patients (right to access 
innovative therapies) and the Health Fund (increase savings, improve efficiency). 
Further analysis based on real world (patient level) data may result more complex 
investigation opportunities of this patient segment and reimbursement category.
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objeCtives: This study aims to determine if the recently proposed model for thera-
peutic positioning reports (IPTs) in Spain is actually being used as a supportive 
tool for pharmaceutical pricing and reimbursement (P&R) decisions whilst deliver-
ing greater transparency and regional market access harmonisation. Methods: 
Primary research was conducted with regional payers on the proposed model of 
IPTs, which contain a comparative evaluation on effectiveness and safety, as well 
as criteria of use, for newly authorized medicines and older medicines which have 
a high potential health or economic impact. This was supplemented by secondary 
research. Results: The publication of IPTs has brought quicker uptake and greater 
homogenization to the market access of certain medicines. Notably, according to 
primary research, protease inhibitors were made available in all autonomous com-
munities (CCAAs) two months after the IPT publication. However, the deadline of 3 
months for the publication of IPTs is generally not being met. As delineated in the 
model and shown by primary research, IPTs are starting to be used as a basis for 
P&R decision-making in Spain and play an important role in the identification of 
the most suitable target patient population. IPTs are also delivering on promises 
of generating consensus amongst the Spanish CCAAs. ConClusions: IPTs are 
being used to support the Inter-ministerial Commission of Medicine Prices and 
the Directorate General of Pharmacy and Basic Services role in P&R. If accepted 
by the majority of the CCAAs, IPTs will also serve as a tool to evaluate and limit 
discrepancies in innovative medicines access throughout Spain. However, there is 
lack of consensus of whether an IPT should include an economic evaluation from 
the start. Contrary to manufacturers, regional payers generally believe its inclusion 
would help with the selection of more cost-effective medicines whilst aiding with 
the adoption of IPTs in general.
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objeCtives: Referral utilization is defined as the number of patients referred and 
seen by physicians. The objective was to establish referral utilization rate among sick 
persons identified at the households, counseled and referred to link hospitals by com-
munity health workers. Sick persons identified were issued with referral and counter 
referral slips to take to the hospital. Methods:  This was a quasi -experimental study 
carried out in two sub- locations in rural Kenya. One hundred community health 
workers were trained on community based referral and counter referral model and 
issued with referral tools. Each was assigned 25 households, instructed to regularly 
visit them in order to identify sick persons, counsel and refer them to link hospitals for 
care. One hundred villages comprising 2209 households with a population of 11,000 
people were covered and referral model implemented for 12 months. Results: A 
total of 322 patients were identified, advised and referred, with a referral response 
rate of 93% (298/322.) Seventy percent were five years and above. The study showed 
that 82% (263/322) of the patients arrived in hospital with referral slip the same day 
